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SUMMARY
Mathematical models of transmission dynamics of infectious diseases provide a useful tool for
investigating the impact of community based control measures. Previously, we used a dynamic
(constant force-of-infection) model for lymphatic filariasis to describe observed patterns of
infection and disease in endemic communities. In this paper, we expand the model to examine
the effects of control options against filariasis by incorporating the impact of age structure of
the human community and by addressing explicitly the dynamics of parasite transmission from
and to the vector population. This model is tested using data for Wuchereria bancrofti
transmitted by Culex quinquefasciatus in Pondicherry, South India. The results show that
chemotherapy has a larger short-term impact than vector control but that the effects of vector
control can last beyond the treatment period. In addition we compare rates of recrudescence
for drugs with different macrofilaricidal effects.
INTRODUCTION
Lymphatic filariasis is a mosquito-borne parasitic
infection that occurs in many parts of the developing
world [1, 2]. The symptoms and disability caused by
this infection have a high social and economic impact
on infected individuals [3, 4]. This, together with the
considerable recent advances made in developing
intervention tools [5], has led to renewed global
interest in controlling or even eliminating this in-
fectious disease [6]. Currently the two main ways of
controlling the disease are vector control and mass
chemotherapy.
Mathematical modelling of parasite transmission
dynamics has proved to be a useful aid to exploring
the probable outcome of community level control
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programmes [7]. Simple mathematical models of
infection have been in existence for filariasis since the
1960s [8–10]. These have provided useful insights into
the dynamics of infection and disease in human
populations [11–14], but have been less helpful in
assessing the impact of community-targeted control
options for two main reasons. They do not explicitly
take account of the age structure of the human
population or of the transmission dynamics of
infection to and from the vector population. However,
both of these factors are thought to be important
[14–16].
In addition to these simple models a stochastic
micro-simulation model of lymphatic filariasis, lym-
fasim, has been developed [17]. Whilst this model is
much more biologically realistic and hence of more
practical use than the simple models it still does not
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explicitly include the dynamics of infection within the
vector population.
Recently, we developed and parameterized a con-
stant force-of-infection cohort model [18]. In this
paper, we extend the basic structure of this model by
incorporating explicitly both host age structure and
vector transmission dynamics in order to provide a
more realistic framework for assessing the con-
sequences of the different intervention options cur-
rently available for filariasis control. The model
includes age-dependent functions of infection as well
as the effects of the demographic age structure of the
human community. The latter is of particular im-
portance for filariasis because of the long lifespan of
the worm.
The model is validated with data from a vector
control programme in Pondicherry, South India, an
area endemic for Bancroftian filariasis transmitted by
the mosquito species Culex quinquefasciatus.
CONCEPTUAL FRAMEWORK
The model described in this paper is developed from
a cohort model described previously [18]. We extend
this model to incorporate the whole transmission
cycle, including the mosquito vector population. This
results in a fully age structured model which is
described by partial differential equations. This type
of framework was first developed for helminth
infections by Anderson and May [19] and has been
successfully developed and validated for schistoso-
miasis [20].
The current model is conceptually similar to the
schistosomiasis model with the important difference
of the inclusion of the insect vector population. In this
model, we treat the mosquito population as being of
a constant size, this being defined in terms of the mean
biting rate per person per month. The dynamics of
infection in the vectors provide a density dependent
mechanism whereby there is a limitation on the
number of L3 larvae that can develop in a mosquito.
The distribution of infection between hosts of
different ages in lymphatic filariasis differs markedly
from schistosomiasis. Whereas schistosomiasis in-
fection is generally most intense in children, the
reverse is true of lymphatic filariasis. This is reflected
in a different force of infection function; we assume
here, that the biting rate increases linearly until the
age of 9 years after which it is constant throughout
adulthood [18]. This reflects both behavioural dif-
ferences and available skin area.
Our previous paper demonstrated that the observed
distribution of infection intensity with age was
consistent with the action of acquired immunity [18].
This mechanism is included in the model where it is
assumed that past experience of infection results in a
reduction in the rate of establishment of new
infections. In the previous paper there was no
statistical evidence for the decay of acquired immunity
and therefore acquired immunity is assumed lifelong
in the current model.
Model inputs and outputs were chosen to reflect the
availability of field data, in particular those available
at the field site in Pondicherry. Input to the model is
the biting rate of mosquitoes and the community
microfilarial load. Output is the age specific prevalence
and intensity of infection. Prevalence is estimated
from intensity using the negative binomial distribution
in the following way. The prevalence of infection at
age a, p(M(a)) is given by
p(M(a))fl 1fi(1›M(a)}k)−k, (1)
where M(a) is the mean intensity at age a and k is
inversely related to the aggregation of the parasite
within the host.
We investigate the behaviour of the model in
response to vector control and chemotherapy. Vector
control is modelled as a percentage reduction in the
vector biting rate over a specified time interval. Mass
chemotherapy (targeted at all age groups) is assumed
to involve an instantaneous reduction in the number
of microfilariae and adult worms at the time of
treatment and a cessation of microfilarial production
over a specified interval. The relative proportions of
the macro- and micro-filaricidal effects can be varied.
MODEL DEVELOPMENT
The model is a system of partial differential equations
describing the patterns of infection over age and time.
We consider two state variables reflecting the infection
status of the human host, the mean worm burden and
the mean microfilarial count (measured as mf per
20 ll of blood) as well as the mean acquired immunity
level (in worm-years). These are all age dependent.
The infection status of vectors is described by the
mean number of infective L3 larvae per mosquito,
which is not age dependent (and therefore described
by an ordinary differential equation). The differential
equations describing the rates of change of the four
variables, mean worm burden (W ), mean microfilarial
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count (M ), mean acquired immunity level (I ) and
mean number of L3 per mosquito (L) are given below:
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Here k(V}H) is the number of bites a host receives per
unit time where k is the number of bites per mosquito
per unit time, V is the number of vectors and H is the
number of hosts ; w
"
is the proportion of L3 which
leave the mosquito when it bites ; w
#
is the proportion
of those L3 leaving the mosquito which enter the host
and s
#
is the proportion of those L3 entering the host
which survive to become adult worms. The rate at
which individuals of age a are bitten is proportional to
h(a), this function exhibits a linear increase up to the
age of 9 years and then becomes unity. L* is the
equilibrium density of L3 larvae (see later). The
parameter l is the death rate of adult worms and b is
a measure of the strength of acquired immunity. The
acquired immunity increases with worm burden.
For microfilariae, a is the production rate of
microfilariae per worm and c is the death rate of
microfilariae. The acquired immunity level is assumed
to be equivalent to the accumulated worm burden,
that is the experience of infection.
In the equation for L3 [eqn (5)], k is the number of
bites per mosquito per unit time; g is the proportion
of bites which are made on infected people and which
result in the mosquito becoming infected; p(a) is the
age distribution of the population under consideration
(Fig. 1) ; r
"
is the death rate of L3s and w
"
is the
proportion of L3 which leave the mosquito when it
bites.
Since L changes more rapidly than the other
variables we assume that it instantaneously adjusts to
equilibrium. Therefore, the model can be simplified by
deriving an expression for this equilibrium. Studies of
parasite dynamics in vectors have suggested that the
relationship between the number of larvae developing
in the vector and the number ingested can take one of
three forms, namely facilitation, limitation or pro-
portionality and that these patterns have major
implications for the overall population dynamics
[16, 21]. For the species under consideration in this
study, Wuchereria bancrofti transmitted by Culex
quinquefasciatus, limitation is the most appropriate
model [16] and we use the following function to
describe the number of infective L3 larvae developing
from an infective host with microfilaria count of M.
Lfl j(1fie−rM/j), (6)
where r and j are constants which were estimated
from data in [22]. This is a logistic growth function
where j is the saturation level and r a measure of the
initial increase in L3 larvae uptake as M increases
from 0.
To derive an expression for L* the equilibrium
number of L3 larvae per mosquito, we need to solve
dL}dtfl 0. Using equation (4) we obtain
L*fl
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a
p(a)(1fif (M ))da
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"
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which can then be used in equation (1).
The function f (M )
f (M )fl 01› Mk(M ) (1fie−r/j)1
−k(M)
(8)
is the population effect of the limitation mechanism in
mosquitoes. It comes from combining the rate of
uptake of infection by mosquitoes [eqn (6)] with the
assumed negative binomial distribution [eqn (1)].
The model is run by assuming that the population
parasite distribution is initially at equilibrium. This
equilibrium is calculated for a given situation by using
the observed monthly biting rate and community mf
load, and then fitting the survival of L3 larvae (s
#
) as
a free parameter. Treatment by chemotherapy or
vector control perturbs this equilibrium.
A computer program to implement this model was
written in fortran. The differential equations were
solved using a numerical finite difference method
(Euler type method).
MODEL VALIDATION
The model was tested against data from an integrated
vector management (IVM) control programme im-
plemented between 1981–5 in Pondicherry (12° N,
80° E), South India [23, 24].
Data on human infection involved three population
surveys in 1981, 1986 and 1989 where 20 ll blood
smears were taken from an age stratified 5% sample
of the population [23–25]. Entomological measure-
ments were taken continuously throughout this
period; resting and biting densities were determined
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Fig. 1. Population age distribution data for Pondicherry (bars) and the age distribution used in the model (line).
Table 1. Default alues for parameters
Symbol Meaning Value (per month) Source
k Number of bites per mosquito 10 [35–37]
j From uptake of L
$
relationship 6 Estimated from [22]
r From uptake of L
$
relationship 0–047 Estimated from [22]
g Proportion of mosquitoes which pick up
infection when biting an infected host
0–37 Estimated from [22]
r
"
Death rate of mosquitoes 5 [38]
w
"
Proportion of L
$
leaving mosquito per bite 0–414 [9]
w
#
Proportion of those L
$
leaving mosquito
which enter host
0–32 [38]
k(M ) Aggregation parameter from negative
binomial distribution
0–0029›0–0236‹M Estimated from data [23, 24]
b Strength of acquired immunity 0–112 Estimated by model
l Death rate of adult worms 0–0104 [3, 39–41]
k(V}H ) Rate at which humans are bitten Initially 5760 [23, 24]
s
#
Proportion of L
$
entering host which
develop into adult worms
1–13‹10−% Estimated by model
a Production rate of microfilaria per worm 2 [42]
c Death rate of microfilaria 0–1 [39, 42]
Table 2. Vector biting rate in control areas from [23, 24 ]
Year 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989
Biting rate
(per month)
5760 576 384 192 192 384 1152 1536 2880 1536
every 2 weeks at a site in the IVM area. These
measurements were continued after the cessation of
IVM.
Parameters for the model validation are reported in
Table 1, with sources. To validate the model, free
parameter s
#
was fitted to the initial age prevalence
profile using maximum likelihood assuming binomial
errors. The model was then run using the observed
values for reductions in vector biting rate (Table 2)
and compared with the data at the end of the control
programme in 1986 and 1989 (Figs. 2–4).
The fit of the model was estimated as the deviance
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Table 3. Statistical comparison of data with model
output and percentage of ariation, R#, in the
prealence data explained by the model
Year v# d.f. P R#
1981 21–3354 10 0–019 93–1%
1986 82–8471 10 0–000 73–2%
1989 172–457 9 0–000 71–5%
(twice the log-likelihood ratio) which is distributed as
v# and is calculated in the following way:
H
!
: prevalence estimated by model has the same
distribution as the data;
H
"
: prevalence estimated by the model has a
different distribution to the data.
Let p
im
be the prevalence in age class i estimated by
the model and p
id
be the actual prevalence in age class
i (the data, ifl 1, …, n). If N is the sample size in each
age class and r is the number infected in each age class
and we assume infection is binomially distributed then
the log likelihood ratio is
fi2 ln
E
F
0Nr 1(pim)r(1fipim)N−r
0Nr 1(pid)r(1fipid)N−r
G
H
flfi2(r ln (p
im
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im
)fir ln (p
id
)
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)),
this is summed over all age groups and the answer
compared to a v# distribution with nfi2 degrees of
freedom.
We also calculated the proportion of the variation
explained by the model, this is equivalent to the
coefficient of determination R# and is calculated using
the following equation:
R#fl 1fi3
(p
i
fipW
i
)#
3(p
i
fipb )#
(9)
where p
i
is the prevalence observed in age class i, pW
i
is
the model prevalence for age class i and pb is the
average prevalence in the year (Table 3).
SIMULATION OF TREATMENT
PROGRAMMES
The model was used to investigate and compare the
long-term impact of two different control strategies :
IVM and single-dose mass chemotherapy.
The aim of IVM is to reduce the number and hence
the biting rate of mosquitoes, which should result in a
decrease in infection rates and ultimately, disease. In
Table 4. Microfilaria intensity data for 1989
including upper confidence limit
Age
Mean mf
intensity
Upper 95%
confidence limit
0–5 0–06 3–19
6–8 0–22 3–07
9–11 0–56 3–28
12–14 0–57 2–87
15–19 0–77 3–13
20–24 0–83 3–04
25–29 0–81 3–18
30–34 0–6 3–09
35–44 0–61 2–93
45–54 0–58 3–00
& 55 0–93 3–38
Pondicherry, vector control was achieved by reducing
the number of sites available for mosquito larval
development [24, 25]. The vector control simulation
described here (Simulation 1) was based on the
reductions in biting rate observed in Pondicherry.
The chemotherapy programmes simulated here
(Simulations 2–4) are based on recommended pro-
cedures rather than an actual programme. We
consider chemotherapy with the two most common
anti-filarial drugs, DEC (diethylcarbamazine citrate)
and ivermectin. WHO currently recommends that
treatment programmes should be based on yearly
mass treatment with a single dose regimen and this is
the type of programme simulated here.
It is thought that the two drugs have different
efficacies. Treatment with either drug results in rapid
clearance of microfilariae followed by a period in
which microfilariae are not produced. Ivermectin has
a somewhat higher efficacy in this regard. However, it
is thought that ivermectin kills very few adult worms
whereas DEC kills a significant proportion of adult
worms. We simulate three different chemotherapy
programmes based on estimated efficacies of the two
drugs. In all the cases, chemotherapy occurs yearly for
the first 5 years and the simulation is run for 10 years.
The following four simulations were carried out.
Simulation 1. Vector control for 5 years with a
reduction in biting rate of 94% followed by a period
of 5 years with no active vector control where biting
rates are still 70% lower than before the programme,
presumably because of residual benefits from reducing
breeding sites [24].
Simulation 2. Chemotherapy with DEC with 80%
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Fig. 2. Graphs of (a) Microfilaria age intensity (mfc) distribution in Pondicherry in 1981. (b) Microfilaria age prevalence (mf
prev) distribution in Pondicherry in 1981. In each case the curve represents the model output and the squares represent the
data. In the case of the prevalence graph we have also included the 95% confidence limits.
coverage; 40% of adult worms are assumed killed and
95% of microfilariae, with no more microfilariae
being produced for 6 months after treatment.
Simulation 3. Chemotherapy with ivermectin with
80% coverage; 10% of adult worms are killed and
99% of microfilariae, with no more microfilariae
being produced for 3 months after treatment.
Simulation 4. Chemotherapy with DEC and iver-
mectin with 80% coverage; 50% of adult worms are
killed and 99% of microfilariae, with no more
microfilariae being produced for 6 months. Note that
the combined effect assumes that the drugs are given
sequentially so that, as a first estimate, the macro-
filaricidal effects are additive [26]. However we also
assume that 99% is the maximum possible micro-
filaricidal effect.
The results of the simulations are shown in three
dimensional surface plots with mean mf count on the
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Fig. 3. Graphs of (a) Microfilaria age intensity distribution in Pondicherry in 1986. (b) Microfilaria age prevalence
distribution in Pondicherry in 1986. In each case the curve represents the model output and the squares represent the data.
In the case of the prevalence graph we have also included the 95% confidence limits.
vertical axis and age and time on the horizontal axes
(Figs 5–8). They are also illustrated as overall changes
in mf count by year (Fig. 9).
RESULTS
Model validation
The statistical analysis of the model validation using
age-prevalence data is shown in Table 3. This includes
the calculation of deviances and the proportion of the
variability explained by the model. For the intensity
data, which were very variable, the means and upper
95% confidence limits for 1989 are shown in Table 4
for illustrative purposes. The lower confidence limits
were close to zero in all cases.
For the baseline data (fitted to model), the model
describes adequately the initial age prevalence curve
(Fig. 2b), explaining 93–1% of the variability (Table
3). The age intensity curve (Fig. 2a) is also well
described by the model. In addition, if we compare the
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Fig. 4. Graphs of (a) Microfilaria age intensity distribution in Pondicherry in 1989. (b) Microfilaria age prevalence
distribution in Pondicherry in 1989. In each case the curve represents the model output and the squares represent the data.
In the case of the prevalence graph we have also included the 95% confidence limits.
predicted equilibrium number of L3 larvae per
mosquito (0–014) with the observed value (0–03 [27])
then we can conclude that overall the model describes
the data reasonably well.
For the 1986 simulation, the model explains 73–2%
of the variability in the observed data and shows a
similar trend, but differs significantly (Table 3) from
the observed data (P! 0–01). Examination of the
graphs of intensity (Fig. 3a) and prevalence (Fig. 3b)
shows that both are underestimated. The under-
estimation is more marked in 1989, where the model
explains 71–5% of the variability and the model is
again statistically significantly different from the
observed data (Table 3). These relationships are
illustrated in Figure 4(a, b).
Simulation of treatment programmes
Figure 5 shows the results of the simulation of vector
control (Simulation 1). As in the programme in
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Fig. 5. Three-dimensional graph to show the microfilaria
age intensity distributions predicted by the model for
10 years of vector control as described in the text.
1·4
1·2
1·0
0·8
0·6
0·4
0·2
0
0
10
20
30
40
50
60
70 10
5
0
YearAge
mf count
Fig. 6. Three-dimensional graph to show the microfilaria
age intensity distribution predicted by the model for 5 years
of treatment with DEC as described in the text.
Pondicherry, it is assumed that during the period of
active vector management (first 5 years), there is a
94% reduction in vector biting rates. For the
following 5 years, active vector management is not
continued, but the structural changes made in the first
5 years mean that vector biting rates remain depressed
at 70% of the pre-control level. The figure predicts a
gradual decrease in human infection levels over this
entire period. The average mf count (over all ages) is
plotted with the results of the other simulations in
Figure 9. Note that since there is no treatment in this
simulation, human infection levels do not decrease
immediately, but only after a time delay as the
reduced biting rates lead eventually to fewer in-
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Fig. 7. Three-dimensional graph to show the microfilaria
age intensity distribution predicted by the model for 5 years
of treatment with ivermectin as described in the text.
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Fig. 8. Three-dimensional graph to show the microfilaria
age intensity distribution predicted by the model for 5 years
of treatment with a combination of DEC and ivermectin as
described in the text.
fections. In particular, the vector management control
programme will avert new infections in the youngest
age groups. After the cessation of active vector
management, the continuing lower biting rates result
in a continued decline in the levels of infections in the
human population.
The population dynamic consequences of the
simulated chemotherapy programmes (Figs 6–9) are
very different from vector control, regardless of the
drug used. There is a direct and immediate reduction
in human infection levels and the treated individuals,
in particular, enjoy an immediate reduction in
infection intensity. In the short term, the chemo-
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Fig. 9. Graph to show how the mean microfilaria intensity changes over the 10 years simulated by the model for the four
different treatment regimens described in the text.
therapy programmes are more effective. However, a
question of interest for chemotherapy programmes is
the reinfection levels after the cessation of treatment.
This appears to depend on the properties of the
treatment, which is explored in Simulations 2–4 (Figs
6–8).
DEC alone (Simulation 2; Figs 6 and 9), which has
a high efficacy against microfilariae and a moderate
efficacy against adult worms, results in an initial sharp
drop in infection levels followed by a sustained
reduction while the treatment programme continues.
When the treatments are discontinued (after year 5),
reinfection occurs but at a low level.
For treatment with ivermectin alone (Simulation 3:
Figs 7 and 9), which has a very high efficacy against
microfilariae but almost no effect on adult worms we
observe a slightly faster initial reduction in infection
levels and sustained very low infection levels while the
treatment programme continues. However, on cess-
ation of treatment the pattern of reinfection is very
different from DEC. Since ivermectin effectively has
no impact on the adult worms, which live on average
for 8 years, the worms are still present once treatment
is discontinued and begin again to produce micro-
filariae. Therefore, there is a very rapid recovery of
microfilariae levels on cessation of control. The
infection level does not return immediately to pre-
control levels as the period of low microfilarial
intensity has led to a reduction in transmission.
The effect of the combination treatment with both
DEC and ivermectin (Simulation 4) is shown in
Figures 8 and 9. This shows an almost identical
pattern to treatment with DEC alone. This result
underlines the importance of considering the macro-
filaricidal activity of the drugs when designing a
chemotherapy programme as this property is par-
ticularly important in determining the recovery rate of
the infection if a treatment programme has a finite life
or is interrupted.
DISCUSSION
In this paper, we have attempted to develop a realistic
transmission model for lymphatic filariasis by ex-
tending an earlier version of the EPIFIL model [18].
This is achieved by incorporating the age structure of
the human community and the dynamics of infection
within the vector population. The inclusion of host
age is necessary not only to account for age-
dependencies in contact with infection [7, 28] but also
because the adult worms are long lived. The explicit
treatment of transmission to and from the vector
population is essential, on the other hand, if the model
is to be used as a predictive tool to estimate the effects
of control.
Here we use the model for two purposes. First, to
assess its value as a tool in predicting the quantitative
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outcomes of control and secondly, to examine and
compare the likely qualitative outcomes of different
control strategies.
When the model predictions for the effects of vector
control are compared to observed data from Pondi-
cherry it is apparent that the qualitative trends were
represented appropriately but that the quantitative
predictive power declined with the period of control.
This could reflect changes in either local transmission
environment or may reflect the impact of uncertainties
in model specification. In this respect, resolution of
uncertainties in three areas of the population biology
of filariasis are likely to improve the quantitative
predictive value of the present model.
First, this model includes acquired, life-long im-
munity to parasite establishment as the only major
form of density dependence operating against in-
fection in humans. Several other mechanisms, such as
an immunity induced reduction in production of
microfilaria and an immunopathological response
may occur [12, 29, 30].
The second area of uncertainty arises because,
despite recent advances in immunodiagnosis [31] and
ultrasound scanning [32, 33], it is still not possible to
measure worm burdens in the field. This is important
in terms of the recrudescence of infection following
chemotherapy.
A third problem with model specification concerns
the exposure rate of individuals to infection in typical
endemic communities. Here, based on indirect evi-
dence [10] and as a first approximation, we have
considered that the vector biting rate on individuals in
the Pondicherry area increases linearly until the age of
9 years after which it settles to a constant value. A
more recent analysis of Cx. quinquefasciatus biting
behaviour in the same area, however, suggests that the
field biting rate may change nonlinearly with the age
of individuals and may exhibit significant gender
differences [28].
Despite these caveats, the results demonstrate the
potential of EPIFIL as an analytical tool for com-
paring the relative, qualitative effectiveness of the
various options for controlling filariasis. The results
suggest that the dynamics of control are funda-
mentally different between the vector and chemo-
therapy-based approaches. Reduction in mean worm
load in the community is gradual with vector control
(duration depending on the lifespan of the parasite)
while the dynamics of reduction in microfilaraemia is
dramatically faster with chemotherapy. For both
methods, the worm population is expected to recover
unless the control measures reduce infection below a
threshold.
Of the three chemotherapy regimens studied (DEC,
ivermectin and combined DEC and ivermectin), our
analysis suggests a superiority of the DEC-based
methods in reducing community microfilarial loads.
Under the same compliance and treatment plans,
DEC alone or in combination is predicted to depress
microfilarial loads much longer than ivermectin alone,
over the 10-year time period under study. This is
because of the much lower macrofilaricidal effect of
ivermectin. The implication of this result is that the
longer term benefits of control will be crucially
dependent on the period of control versus the
longevity of the worm. Here we assume mean expected
life span to be 8 years (see [18]), although values as
low as 3–5 years have been estimated [14].
The results also suggest that there is relatively little
benefit in combining ivermectin with DEC, although
DEC adds considerably to the benefits of ivermectin
because of the macrofilaricidal effect. This has
important implications for the proposed combination
of Albendazole with ivermectin for filariasis control in
Africa (WHO). Since Albendazole is reportedly
macrofilaricidal [34] the combination should have
enhanced long-term effectiveness, even though the
difference would not be apparent in the short term
when the much more immediate efficacy of ivermectin
would dominate.
In conclusion, we have developed a dynamic model
framework for bancroftian filariasis, which may
adequately describe the transmission of this parasite,
at least in qualitative terms. The framework es-
tablishes the basis on which further refinements can be
made leading to the development of a robust decision
making tool for filariasis control.
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